Internal Radiation Therapies : Radioimmunotherapies
Zevalin® (Ibritumomab tiuxetan) 90Y
Ibritumomab Tiuxetan, trade name Zevalin, is a monoclonal antibody approved by the FDA for use in patients with follicular lymphoma whose disease has recurred, or who have persistent disease after initial treatment. Those individuals whose slow growing follicular lymphoma has turned into an aggressive B-cell non-Hodgkin's lymphoma (NHL) can also be treated with Zevalin. Those who have previously been treated with Rituximab also may receive Zevalin. Zevalin is being studied for different stages of lymphoma, even as an initial treatment. It is given as an injection in the veins and it is usually administered along with Rituximab. For more information on Zevalin, please go to http://www.zevalin.com/.
Bexxar® (Tositumomab) 131I
Bexxar is a monoclonal antibody that has a radioactive substance called iodine 131 attached to it. Bexxar is indicated for the treatment of patients with non-Hodgkin's lymphoma who have already had chemotherapy and received Rituximab. Bexxar’s treatment regimen is a single injection. For more information on Bexxar, please go to http://www.bexxar.com/.
GliaSite® (Iotrex®) 125I
Gliasite is a procedure performed after the surgical removal of malignant brain tumors. It delivers radiation to delicate parts of the brain. Once a tumor has been removed, a Gliasite balloon catheter is inserted into the remaining cavity. The catheter stays in the cavity for several days until the patient has recovered from surgery. It is then slowly filled with a solution of liquid radiation called Iotrex. The Iotrex radiation is delivered over the course of about a week. For more information on GliaSite, please go to http://www.gliasite.com/.
Chromic phosphate P-32 is an infused radioactive isotope often used to treat brain-related issues, but it can be used at other sites as well. The course of treatment is a one time infusion. For more information on P-32, please contact our research unit.
|Body Sites||Multiple Sites||Brain||Brain|
For more information, please view the following websites:
- Cancer Net at http://www.cancer.net/portal/site/patient
- National Cancer Institute (NCI) at http://www.cancer.gov/
- American Cancer Society at http://www.cancer.org/docroot/home/index.asp
- Radioisotope Therapy (RIT)
With radioisotope therapy (RIT), a liquid form of radiation is administered internally through infusion or injection. The rationale behind RIT is to treat cancerous cells with minimal damage to the normal surrounding tissue. RIT uses a radioactive substance, such as a radiolabeled monoclonal antibody, that travels in the blood directly to tissues at the cancer site. These therapies are not normally the first approach used to fight a patient’s cancer. Instead, they are more likely to be used after other therapies have not achieved their desired results. There are numerous barriers to radioisotope therapy including issues of access, acquisition of radioisotopes, radiation protection regulations, and cost.